Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thalidomide + nab-paclitaxel + gemcitabine + epirubicin
- Development stage
- Phase 2
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of four anticancer agents with different mechanisms of action. Thalidomide is an immunomodulatory drug with anti-angiogenic properties and NF-κB inhibition. Nab-paclitaxel (Abraxane) is a taxane that stabilizes microtubules and prevents cell division. Gemcitabine is a nucleoside analog that interferes with DNA synthesis. Epirubicin is an anthracycline topoisomerase II inhibitor that interferes with DNA and RNA synthesis.
02
Targets
CRBN (Cereblon)CDA (Cytidine deaminase)DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))NF-κB
Beyond the preview
Go deeper on thalidomide + nab-paclitaxel + gemcitabine + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thalidomide + nab-paclitaxel + gemcitabine + epirubicin.